POM-V Prescription Required Companion Animal

Fatrovax RHD Suspension for Injection for Rabbits

Active ingredient: Rabbit haemorrhagic disease virus

Form

Injection

Species

Rabbits

Manufacturer

Fatro S.p.A.

VMD MA No.

11557/5000

What it's used for

For active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of Rabbit Haemorrhagic Disease...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Rabbit haemorrhagic disease...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Fatrovax RHD Suspension for Injection for Rabbits — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For active immunisation of rabbits from the age of 28 days to reduce mortality,
infection, clinical signs and organ lesions of Rabbit Haemorrhagic Disease
caused by RHDV and RHDV2.
Onset of immunity: 1 week
Duration of immunity: 1 year

Issued: September 2021
AN: 01087/2019

Subcutaneous use.
Vaccination schedule: Administer one dose from 28-30 days of age onward.
Revaccinate every 12 months.
Vaccination using the single dose presentation (0.5 ml)
The pre-filled glass syringes needs to be attached to the needle included in
the package. Administer one dose by subcutaneous injection.
Vaccination using multidose presentations (50 doses (25 ml) or 200 doses
(100 ml))
The elastomer stoppers of the polypropylene bottles need to be punctured with
a needle (attached to a syringe) to extract the appropriate volume for
vaccination (0.5 ml per animal). Administer one dose by subcutaneous
injection.
Before use allow the vaccine to reach room temperature.
Shake well before use to resuspend the sedimentation

None

A small painless palpable nodule (maximum 5.2 mm diameter) may be very
commonly observed at the injection site, resolving within 12 days.
A transient temperature increase up to 1.65 °C can very commonly occur in
the first week following vaccination.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports)

Vaccinate healthy animals only.
Low levels of maternally derived antibodies against RHD virus do not interfere
with vaccine efficacy. However, no information is available on the use of the
vaccine in animals with high levels of maternally derived antibodies. Thus, in
situations where a high level of maternally derived antibodies against RHD
virus is expected, the vaccination scheme must be adjusted accordingly.

Special precautions for use in animals
Pregnant does should be handled with special care to avoid stress and risk of
abortion.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show
the package leaflet or the label to the physician.

Interaction
No information is available on the safety and efficacy of this vaccine when used
with any other veterinary medicinal product. A decision to use this vaccine
before or after any other veterinary medicinal product therefore needs to be
made on a case by case basis.

Store and transport refrigerated (2 °C-8 °C).
Do not freeze.
Protect from light

commonly observed at the injection site, resolving within 12 days.
A transient temperature increase up to 1.65 °C can very commonly occur in
the first week following vaccination.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports)
4.7 Use during pregnancy, lactation or lay
Can be used during pregnancy.

Issued: September 2021
AN: 01087/2019
4.8 Interaction with other medicinal products and other forms of
Interaction
No information is available on the safety and efficacy of this vaccine when used
with any other veterinary medicinal product. A decision to use this vaccine
before or after any other veterinary medicinal product therefore needs to be
made on a case by case basis.
4.9 Amounts to be administered and administration route
Subcutaneous use.
Vaccination schedule: Administer one dose from 28-30 days of age onward.
Revaccinate every 12 months.
Vaccination using the single dose presentation (0.5 ml)
The pre-filled glass syringes needs to be attached to the needle included in
the package. Administer one dose by subcutaneous injection.
Vaccination using multidose presentations (50 doses (25 ml) or 200 doses
(100 ml))
The elastomer stoppers of the polypropylene bottles need to be punctured with
a needle (attached to a syringe) to extract the appropriate volume for
vaccination (0.5 ml per animal). Administer one dose by subcutaneous
injection.
Before use allow the vaccine to reach room temperature.
Shake well before use to resuspend the sedimentation
4.10 Overdose (symptoms, emergency procedures, antidotes), if
necessary
No different local reactions were observed other than those described in
section 4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.